Peer-review started: September 2, 2020
First decision: September 21, 2020
Revised: September 23, 2020
Accepted: November 19, 2020
Article in press: November 19, 2020
Published online: December 15, 2020
Processing time: 99 Days and 12.2 Hours
There is recently a concern regarding the reinfection and reactivation of previously reCoVered coronavirus disease 2019 (CoVID-19) patients.
To summarize the recent findings and reports of CoVID-19 reinfection in patients previously reCoVered from the disease.
This study was a systematic review of current evidence conducted in August 2020. The authors studied the probable reinfection risk of novel coronavirus (CoVID-19). We performed a systematic search using the keywords in online databases. The investigation adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist to ensure the reliability and validity of this study and results.
We reviewed 31 studies. Eight studies described reCoVered patients with reinfection. Only one study reported reinfected patients who died. In 26 studies, there was no information about the status of the patients. Several studies indicated that reinfection is not probable and that post-infection immunity is at least temporary and short.
Based on our review, we concluded that a positive polymerase chain reaction retest could be due to several reasons and should not always be considered as reinfection or reactivation of the disease. Most relevant studies in positive retest patients have shown relative and probably temporary immunity after the reCoVery of the disease.
Core Tip: The reinfection in patients reCoVered from coronavirus disease 2019 (CoVID-19) could create a serious challenge in tackling the CoVID-19 pandemic as the reCoVered patients could be a source of virus spread in society. Previous studies have found a positive viral ribonucleic acid test in some of the discharged CoVID-19 patients 10 to 27 d after reCoVery. Recurrence of CoVID-19 after reCoVery should be differentiated from secondary medical conditions such as super infection, pulmonary embolism, or persistent ribonucleic acid virus that can be disCoVered in respiratory specimens in clinically cured CoVID-19 patients. This review aims to assist a systematic compilation of severe acute respiratory syndrome coronavirus 2 reactivation in reCoVered CoVID-19 patients.